UK markets close in 2 hours 34 minutes

BioMarin Pharmaceutical Inc. (0HNC.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
89.36+5.21 (+6.19%)
As of 3:20PM GMT. Market open.

BioMarin Pharmaceutical Inc.

770 Lindaro Street
San Rafael, CA 94901
United States
415 506 6700

Full-time employees

Key executives

NameTitlePayExercisedYear born
Mr. Jean-Jacques Bienaime M.B.A., MBAChairman & CEO3.6M8.37M1953
Mr. Jeffrey Robert AjerExec. VP & Chief Commercial Officer1.17MN/A1962
Dr. Henry J. FuchsPres of Worldwide R&D1.55MN/A1958
Mr. Brian R. MuellerExec. VP & CFON/AN/A1974
Ms. Andrea L. AcostaGroup VP & Chief Accounting OfficerN/AN/A1979
Dr. C. Greg Guyer Ph.D.CTO and Exec. VP of Global Manufacturing & Technical OperationsN/AN/AN/A
Mr. Lon Cardon Ph.D.Chief Scientific Strategy OfficerN/AN/AN/A
Traci McCartyVP of Investor RelationsN/AN/AN/A
Mr. George Eric DavisExec. VP, Gen. Counsel & Sec.N/AN/A1971
Mr. Philip Lo ScalzoSr. VP & Chief Compliance OfficerN/AN/AN/A
Amounts are as of 31 December 2019, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


BioMarin Pharmaceutical Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme for adult patients with PKU; and Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV Type A, a lysosomal storage disorder. Its clinical and pre-clinical product pipeline includes valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; vosoritide, a peptide therapeutic that is in Phase III clinical trial for the treatment of achondroplasia, a form of disproportionate short stature in humans; and BMN 307, an AAV5 mediated gene therapy to normalize blood phenylalanine concentration levels in patients with phenylketonuria. The company serves specialty pharmacies; and end-users, such as hospitals and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has collaboration and license agreements with Sarepta Therapeutics and Asubio Pharma Co., Ltd.; and a preclinical collaboration and license agreement with DiNAQOR AG for the development of gene therapies to treat rare genetic cardiomyopathies. The company was founded in 1996 and is headquartered in San Rafael, California.

Corporate governance

BioMarin Pharmaceutical Inc.’s ISS governance QualityScore as of 2 December 2020 is 4. The pillar scores are Audit: 2; Board: 4; Shareholder rights: 5; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.